Eisai Co., Ltd. (OTCMKTS:ESALY – Get Free Report)’s stock price dropped 2.1% during trading on Wednesday. The company traded as low as $61.00 and last traded at $61.51. Approximately 331,800 shares were traded during trading, an increase of 445% from the average session volume of 60,916 shares. The stock had previously closed at $62.8350.
Eisai Stock Down 2.1%
The firm has a market capitalization of $17.64 billion, a P/E ratio of 70.70, a PEG ratio of 2.46 and a beta of 0.31. The firm’s 50-day moving average is $61.51 and its 200 day moving average is $61.51. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.77 and a current ratio of 2.20.
Eisai Company Profile
Eisai is a Japan-based pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Its research and commercial activities focus primarily on neurology and oncology, alongside other therapeutic areas. The company’s medicines include lecanemab, marketed as Leqembi for Alzheimer’s disease in certain markets, and lenvatinib, marketed as Lenvima for several types of cancer. Eisai also offers treatments for conditions including insomnia, epilepsy and cancer. Founded in Japan in 1941, Eisai serves patients and healthcare providers in Japan and other markets around the world.
Further Reading
- Five stocks we like better than Eisai
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Eisai Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eisai and related companies with MarketBeat.com's FREE daily email newsletter.
